NAD+

Source-reported examples · not treatment recommendations

Amount

50–100 mg per day

Frequency

Once daily

Cycle / observation period

8–16 weeks

Route / research model

Subcutaneous

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

• NAD+ is a cellular cofactor involved in energy metabolism. That biological importance does not establish that an NAD+ infusion improves energy, cognition or longevity in a person. The small infusion study reviewed here measured blood and urine chemistry over hours. Separately, FDA has reported safety concerns with some compounded injectable NAD+ products. Both the efficacy question and the product-quality question deserve attention. ^{[1] [2]}
• Grant and colleagues enrolled 11 men, assigning eight to NAD+ and three to saline. They monitored a six-hour infusion and sampled blood and urine through eight hours. Plasma NAD+ did not rise during the first two hours; later biochemical changes and urinary excretion helped characterize the administered material's metabolic fate. No adverse events were observed during the infusion in this small study. ^[1]
• In a January 2026 warning letter to a specific compounder, FDA described three patients referred to an emergency department after receiving a product containing NAD+. An unopened vial from the same lot was reported to contain excessive bacterial endotoxin. This is a documented product-quality finding, not proof that every NAD+ preparation has the same contamination. ^[3]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 26 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.

1. Infusion pilot
2. FDA compounding alert
3. FDA warning letter
4. Pharmaceuticals (Basel)Further reading · Listed in reference bibliography.
5. Current Psychiatry Research and ReviewsFurther reading · Listed in reference bibliography.
6. PMC (Pharmacology & Potential Implications of NAD+)Further reading · Listed in reference bibliography.
7. Frontiers in Aging NeuroscienceFurther reading · Listed in reference bibliography.
8. American Journal of Physiology (PubMed)Further reading · Listed in reference bibliography.
9. CDC Pink Book (Chapter 6)General guidance · Listed in reference bibliography.
10. CDC Subcutaneous Injection GuideGeneral guidance · Listed in reference bibliography.
11. NCBI BookshelfFurther reading · Listed in reference bibliography.
12. PMC (Subcutaneous Drug Injection Review)Further reading · Listed in reference bibliography.
13. Four-Day NAD+ IV Tolerability Pilot : Retrospective real-world review using 500 mg NAD+ IV once daily for four consecutive days with 30-day follow-up.Further reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.